<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141189</url>
  </required_header>
  <id_info>
    <org_study_id>BezmialemVU fetal surveillance</org_study_id>
    <nct_id>NCT04141189</nct_id>
  </id_info>
  <brief_title>Comparison of Follow-up Protocols in Terms of Fetal, Neonatal and Maternal Results in Intrauterine Growth Retardation</brief_title>
  <official_title>Comparison of Follow-up Protocols in Terms of Fetal, Neonatal and Maternal Results in Intrauterine Growth Retardation: a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bezmialem Vakif University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bezmialem Vakif University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be undertaken to determine whether the frequency of fetal surveillance can be
      safely reduced from bi-weekly to weekly in the case of fetusus with intrauterine growth
      restriction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective randomized study, the cases whose fetal weight predicted by
      ultrasonography (USG) between the 28th and 37th weeks of gestation are below 10percentile
      according to the World Health Organization (WHO) normograms. The cases will be divided into
      two groups as group 1:weekly and group 2:bi-weekly (twice-weekly) The cases will be evaluated
      by fetal Doppler, amniotic fluid volume, nonstress test (NST) and maternal preeclampsia
      tests.Maternal severe hypertension/preeclampsia, category 3 NST, oligohydramnios (after 37
      weeks amniotic fluid index &lt;5; after 34 weeks single deepest pocket &lt;2 cm) ,pathological
      doppler (before 34 weeks reverse flow in an umbilical artery , after 34 weeks absent
      end-diastolic flow in an umbilical artery) in cases of birth decision will be taken. Cases
      without the above mentioned complications will be delivered between 38 weeks 3 days and 39
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">November 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neonatal hospital stay</measure>
    <time_frame>3 months</time_frame>
    <description>duration of neonatal hospital stay (days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>antenatal hospital stay</measure>
    <time_frame>3 months</time_frame>
    <description>duration of antenatal hospital stay (days)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>gestational age at delivery</measure>
    <time_frame>24 hours</time_frame>
    <description>gestational age at delivery as days (e.g. 261days)</description>
  </other_outcome>
  <other_outcome>
    <measure>neonatal hospital stay</measure>
    <time_frame>3 months</time_frame>
    <description>duration of neonatal hospital stay (days)</description>
  </other_outcome>
  <other_outcome>
    <measure>acidosis</measure>
    <time_frame>24 hours</time_frame>
    <description>fetal acidosis (normal cord-blood pH ranges from 7.14 to 7.4 during labor, values below 7.14 are considered to be acidosis)</description>
  </other_outcome>
  <other_outcome>
    <measure>perinatal death</measure>
    <time_frame>3 months</time_frame>
    <description>The number of perinatal deaths. Perinatal death is a fetal death (stillbirth) or an early neonatal death (first 24 hours after birth)</description>
  </other_outcome>
  <other_outcome>
    <measure>cesarean delivery</measure>
    <time_frame>24 hours</time_frame>
    <description>The number of births by cesarean section</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Fetal Surveillance</condition>
  <condition>Intrauterine Growth Restriction</condition>
  <arm_group>
    <arm_group_label>weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weekly fetal surveillance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bi-weekly (twice-weekly)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bi-weekly fetal surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>weekly</intervention_name>
    <description>fetal surveillance frequency</description>
    <arm_group_label>weekly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bi-weekly</intervention_name>
    <description>fetal surveillance frequency</description>
    <arm_group_label>bi-weekly (twice-weekly)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  28-37 weeks pregnant women with estimated fetal weight below 10 percentile

          -  singlton pregnancy

        Exclusion Criteria:

          -  maternal preeclampsia

          -  maternal systemic disease (pregestational diabetes, gestational diabetes mellitus a2,
             antiphospholipid antibody syndrome, chronic kidney disease)

          -  oligohydramnios (after 34 weeks amniotic fluid index &lt;5; before 34 weeks single
             deepest pocket &lt;2 cm)

          -  pathological doppler (high umbilical artery resistance index, absence of end-diastolic
             flow velocity in the umbilical artery, reverse flow in the umbilical artery, brain
             sparing effect in middle cerebral artery, abnormal ductus venosus flow)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>taha takmaz, MD</last_name>
    <phone>+902124531700</phone>
    <email>thtkmz@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>serdar kutuk, MD</last_name>
    <phone>+902124531700</phone>
    <email>mehmetserdarkutuk@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bezmialem VakÄ±f University Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taha Takmaz, MD</last_name>
      <phone>+905548707340</phone>
      <email>thtkmz@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intrauterine Growth Restriction</keyword>
  <keyword>fetal surveillance</keyword>
  <keyword>fetal doppler</keyword>
  <keyword>fetal growth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

